These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37870303)

  • 1. A GMP-Compliant Procedure for the Generation of Gene-Modified T cells.
    Savvopoulos N; Stampolitis K; Alexandropoulos G; Kefala D; Lysandrou M; Zacharioudaki V; Tsolakos N; Spyridonidis A
    J Vis Exp; 2023 Oct; (200):. PubMed ID: 37870303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can academic structures improve access to CAR-T cells?].
    Le Guen C; Grain A; Le Calvez B; Saiagh S; Vrignaud F; Eveillard M; Clémenceau B; Zahar MB
    Bull Cancer; 2024 Jan; 111(1):62-72. PubMed ID: 38030508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Deschamps M; Decot V; Giverne C; Pinturaud M; Vaissié A; Parquet N; Olivero S; Anne-Claire M; Bay JO; Yakoub-Agha I; Ferrand C
    Bull Cancer; 2020 Jan; 107(1S):S85-S93. PubMed ID: 31547937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes.
    Ravindranath A; Dubey A; Suresh S; Chaudhuri G; Chirmule N
    Cytotherapy; 2022 Feb; 24(2):101-109. PubMed ID: 34753677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
    Abou-El-Enein M; Elsallab M; Feldman SA; Fesnak AD; Heslop HE; Marks P; Till BG; Bauer G; Savoldo B
    Blood Cancer Discov; 2021 Sep; 2(5):408-422. PubMed ID: 34568831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
    Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.
    Poorebrahim M; Sadeghi S; Fakhr E; Abazari MF; Poortahmasebi V; Kheirollahi A; Askari H; Rajabzadeh A; Rastegarpanah M; Linē A; Cid-Arregui A
    Crit Rev Clin Lab Sci; 2019 Sep; 56(6):393-419. PubMed ID: 31314617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
    Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
    Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
    Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
    Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
    Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
    Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
    Front Immunol; 2019; 10():2361. PubMed ID: 31649672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.
    Castella M; Caballero-Baños M; Ortiz-Maldonado V; González-Navarro EA; Suñé G; Antoñana-Vidósola A; Boronat A; Marzal B; Millán L; Martín-Antonio B; Cid J; Lozano M; García E; Tabera J; Trias E; Perpiña U; Canals JM; Baumann T; Benítez-Ribas D; Campo E; Yagüe J; Urbano-Ispizua Á; Rives S; Delgado J; Juan M
    Front Immunol; 2020; 11():482. PubMed ID: 32528460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GMP CAR-T cell production.
    Gee AP
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can Cytokine-induced killer cells overcome CAR-T cell limits.
    Cappuzzello E; Vigolo E; D'Accardio G; Astori G; Rosato A; Sommaggio R
    Front Immunol; 2023; 14():1229540. PubMed ID: 37675107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
    Labbé RP; Vessillier S; Rafiq QA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
    Gardner RA; White C; Elsallab M; Farnia S; Fraint E; Grilley B; Bateman-House A; Grupp SA; Kenderian S; Locke FL; Nikiforow S; Oluwole OO; Rouce RH; Spiegel J; Shah NN; Sharma A; Komanduri K; Gill S
    Transplant Cell Ther; 2024 Aug; 30(8):776-787. PubMed ID: 38762057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CART manufacturing process and reasons for academy-pharma collaboration.
    Egri N; Ortiz de Landazuri I; San Bartolomé C; Ortega JR; Español-Rego M; Juan M
    Immunol Lett; 2020 Jan; 217():39-48. PubMed ID: 31669547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
    van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
    Wang L; Gong W; Wang S; Neuber B; Sellner L; Schubert ML; Hückelhoven-Krauss A; Kunz A; Gern U; Michels B; Hinkelbein M; Mechler S; Richter P; Müller-Tidow C; Schmitt M; Schmitt A
    Cytotherapy; 2019 May; 21(5):566-578. PubMed ID: 30910382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Challenges in Process Development of Cellular Therapies.
    Highfill SL; Stroncek DF
    Curr Hematol Malig Rep; 2019 Aug; 14(4):269-277. PubMed ID: 31278568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.